The phase 3 bepirovirsen trial introduces a clinically important distinction: this antisense oligonucleotide therapy targets viral RNA rather than simply suppressing replication. For practitioners managing the 296 million people globally with chronic hepatitis B, this represents a potentially transformative treatment option addressing a critical unmet need.
Key clinical implications include bepirovirsen’s ability to target hepatitis B surface antigen production—a mechanism unavailable with current first-line nucleoside analogues. The trial’s primary endpoints measuring sustained HBsAg loss and undetectable HBV DNA align with established WHO definitions of functional cure, marking a meaningful advancement beyond the viral suppression paradigm that dominates current treatment strategies. As functional cure remains the ultimate therapeutic goal for chronic hepatitis B, this novel approach may reshape treatment algorithms and patient management strategies across diverse clinical settings.
Read the full article on GMJ Newsroom.
Was this article helpful?
